Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinically actionable pharmacogenomic variants for anticancer therapy in Nigeria: first comprehensive variant profiling in underrepresented Nigerian cohorts.

BMC medical genomics - 9 Feb 2026

Ukpe Michael Pius, Ezeanuka Anastecia Chinasa

Abstract excerpt

BACKGROUND: Advances in pharmacogenomic research have ushered in a new era of precision medicine in cancer care. However, evidence on the effects of pharmacogenomic variants on anticancer drug efficacy and safety in the Nigerian population is scarce. As a result, pharmacogenomic testing is not currently included in cancer care in Nigeria. This study aimed to investigate the minor allele frequencies (MAFs) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Methyltransferases

Share to Neoplasms

Share to Nigeria

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Source

Open in PubMed Open full text

Identifiers

PMID: 41664142
DOI: 10.1186/s12920-026-02324-7
PMCID: PMC12997735

Genes

CYP3A5
DPYD
TPMT
REST

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinically actionable pharmacogenomic variants for anticancer therapy in Nigeria: first comprehensive variant profiling in underrepresented Nigerian cohorts.PMID 41664142Read ↗

Clinically Actionable Pharmacogenomic Variants for Anticancer Therapy in Nigeria: First Comprehensive Variant Profiling in Underrepresented Nigerian CohortsSemantic proximity Read ↗

Germline oncopharmacogenetics, a promising field in cancer therapy.Semantic proximity Read ↗

Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented Population.Semantic proximity Read ↗

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.Semantic proximity Read ↗

How to Consider Rare Genetic Variants in Personalized Drug Therapy.Semantic proximity Read ↗

Pharmacogenomic survey of Qatari populations using whole-genome and exome sequences.Semantic proximity Read ↗

CYP2D6 Pharmacogenetics in Nigerian Sickle Cell Disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa (iPROTECTA) programSemantic proximity Read ↗

Opportunistic analysis of clinically actionable DPYD gene variants in a germline testing cohort in India.Semantic proximity Read ↗

Pharmacogenomic analysis and clinical annotation of 635 patients.Semantic proximity Read ↗

Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.Semantic proximity Read ↗

Cancer Genomics Research in Nigeria: A Scoping Review Protocol v1Semantic proximity Read ↗

Pharmacogenomic landscape of a Moroccan cohort: enhancing global diversity and addressing the North African gap.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.